High-intensity intermittent training ameliorates methotrexate-induced acute lung injury
© 2024. The Author(s)..
Inflammation and oxidative stress are recognized as two primary causes of lung damage induced by methotrexate, a drug used in the treatment of cancer and immunological diseases. This drug triggers the generation of oxidants, leading to lung injury. Given the antioxidant and anti-inflammatory effects of high-intensity intermittent training (HIIT), our aim was to evaluate the therapeutic potential of HIIT in mitigating methotrexate-induced lung damage in rats. Seventy male Wistar rats were randomly divided into five groups: CTL (Control), HIIT (High-intensity intermittent training), ALI (Acute Lung Injury), HIIT+ALI (pretreated with HIIT), and ALI + HIIT (treated with HIIT).HIIT sessions were conducted for 8 weeks. At the end of the study, assessments were made on malondialdehyde, total antioxidant capacity (TAC), superoxide dismutase (SOD), glutathione peroxidase (Gpx), myeloperoxidase (MPO), interleukin 10 (IL-10), tumor necrosis factor-alpha (TNF-α), gene expression of T-bet, GATA3, FOXP3, lung wet/dry weight ratio, pulmonary capillary permeability, apoptosis (Caspase-3), and histopathological indices.Methotrexate administration resulted in increased levels of TNF-α, MPO, GATA3, caspase-3, and pulmonary edema indices, while reducing the levels of TAC, SOD, Gpx, IL-10, T-bet, and FOXP3. Pretreatment and treatment with HIIT reduced the levels of oxidant and inflammatory factors, pulmonary edema, and other histopathological indicators. Concurrently, HIIT increased the levels of antioxidant and anti-inflammatory factors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
BMC pulmonary medicine - 24(2024), 1 vom: 20. Jan., Seite 45 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rajizadeh, Mohammad Amin [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.01.2024 Date Revised 23.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12890-024-02853-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367361663 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367361663 | ||
| 003 | DE-627 | ||
| 005 | 20240123232024.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240121s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12890-024-02853-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1268.xml |
| 035 | |a (DE-627)NLM367361663 | ||
| 035 | |a (NLM)38245672 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rajizadeh, Mohammad Amin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a High-intensity intermittent training ameliorates methotrexate-induced acute lung injury |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.01.2024 | ||
| 500 | |a Date Revised 23.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Inflammation and oxidative stress are recognized as two primary causes of lung damage induced by methotrexate, a drug used in the treatment of cancer and immunological diseases. This drug triggers the generation of oxidants, leading to lung injury. Given the antioxidant and anti-inflammatory effects of high-intensity intermittent training (HIIT), our aim was to evaluate the therapeutic potential of HIIT in mitigating methotrexate-induced lung damage in rats. Seventy male Wistar rats were randomly divided into five groups: CTL (Control), HIIT (High-intensity intermittent training), ALI (Acute Lung Injury), HIIT+ALI (pretreated with HIIT), and ALI + HIIT (treated with HIIT).HIIT sessions were conducted for 8 weeks. At the end of the study, assessments were made on malondialdehyde, total antioxidant capacity (TAC), superoxide dismutase (SOD), glutathione peroxidase (Gpx), myeloperoxidase (MPO), interleukin 10 (IL-10), tumor necrosis factor-alpha (TNF-α), gene expression of T-bet, GATA3, FOXP3, lung wet/dry weight ratio, pulmonary capillary permeability, apoptosis (Caspase-3), and histopathological indices.Methotrexate administration resulted in increased levels of TNF-α, MPO, GATA3, caspase-3, and pulmonary edema indices, while reducing the levels of TAC, SOD, Gpx, IL-10, T-bet, and FOXP3. Pretreatment and treatment with HIIT reduced the levels of oxidant and inflammatory factors, pulmonary edema, and other histopathological indicators. Concurrently, HIIT increased the levels of antioxidant and anti-inflammatory factors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute lung injury | |
| 650 | 4 | |a High-intensity intermittent training | |
| 650 | 4 | |a Inflammatory factors | |
| 650 | 4 | |a Methotrexate | |
| 650 | 4 | |a Mohammad Amin Rajizadeh, Mahdiyeh Haj Hosseini, Mina Bahrami, Faegheh Bahri and Fahimeh Rostamabadi equally contributed as first author. | |
| 650 | 4 | |a Oxidative stress | |
| 650 | 4 | |a Therapeutic effects | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 650 | 7 | |a Interleukin-10 |2 NLM | |
| 650 | 7 | |a 130068-27-8 |2 NLM | |
| 650 | 7 | |a Methotrexate |2 NLM | |
| 650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
| 650 | 7 | |a Caspase 3 |2 NLM | |
| 650 | 7 | |a EC 3.4.22.- |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Glutathione Peroxidase |2 NLM | |
| 650 | 7 | |a EC 1.11.1.9 |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Superoxide Dismutase |2 NLM | |
| 650 | 7 | |a EC 1.15.1.1 |2 NLM | |
| 650 | 7 | |a Forkhead Transcription Factors |2 NLM | |
| 700 | 1 | |a Hosseini, Mahdiyeh Haj |e verfasserin |4 aut | |
| 700 | 1 | |a Bahrami, Mina |e verfasserin |4 aut | |
| 700 | 1 | |a Bahri, Faegheh |e verfasserin |4 aut | |
| 700 | 1 | |a Rostamabadi, Fahimeh |e verfasserin |4 aut | |
| 700 | 1 | |a Bagheri, Fatemeh |e verfasserin |4 aut | |
| 700 | 1 | |a Khoramipour, Kayvan |e verfasserin |4 aut | |
| 700 | 1 | |a Najafipour, Hamid |e verfasserin |4 aut | |
| 700 | 1 | |a Bejeshk, Mohammad-Abbas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC pulmonary medicine |d 2001 |g 24(2024), 1 vom: 20. Jan., Seite 45 |w (DE-627)NLM114960313 |x 1471-2466 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:20 |g month:01 |g pages:45 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12890-024-02853-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 1 |b 20 |c 01 |h 45 | ||